LRRC32 and neoplasm: As a result of the predominance of activated platelets and Tregs in the lung cancer TME, as well as the hijacking of GARP by tumor cells, a menacing, TGF-β1-enriched milieu is established, which is likely to contribute to tumor progression, resistance to tumor-targeted therapies and a poor prognosis [26,27,28].